FDA Threatens to Block Imports from Two Indian Drug Companies for CGMP VIolations
The Food and Drug Administration threatened two Indian drug companies with refusal of their products at the border for violations of current good manufacturing practice requirements. FDA told Posh Chemicals in a warning letter Aug. 2 that active pharmaceutical ingredients…
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
(APIs) from its facility in Hyderabad may face import alert and detention without physical examination unless CGMP violations are corrected (here). And in a warning letter sent Aug. 9, FDA told Sentiss Pharma (formerly Promed Exports) that it will continue to refuse finished pharmaceuticals already subject to DWPE from the company’s Khera Nihla Village facility for uncorrected CGMP violations (here).